Daxor Corporation Contracted to Adapt Its Blood Volume Analyzer Technology for U.S. Air Force NeedsGlobeNewsWire • 03/09/20
Daxor Corporation Announces Closing of $2.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 03/06/20
Daxor Corporation Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-MarketGlobeNewsWire • 03/03/20
Daxor Corporation Announces Engagement with Hospitals and Government for Use of the Blood Volume Analyzer (BVA-100®) to Stem COVID-19 DeathsGlobeNewsWire • 03/02/20
New Research Further Demonstrates Clinical Superiority of Daxor Corporation’s Blood Volume Analyzer (BVA-100®) in Critical CareGlobeNewsWire • 02/20/20
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th CongressGlobeNewsWire • 02/12/20
Novel Study from Yale University Utilizes Daxor’s Blood Volume Analyzer (BVA-100®) to Uncover Important Mechanism for Drug EmpagliflozinGlobeNewsWire • 11/21/19
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2019GlobeNewsWire • 11/12/19
Daxor to Present at the Inaugural MicroCap Rodeo Investor Conference on October 15, 2019 at 1:30 PM Central TimeGlobeNewsWire • 10/10/19
Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of HypertensionGlobeNewsWire • 09/24/19